SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ΑLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY

Stine Ulrik Mikkelsen, Lasse Kjær, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Vibe Skov, Christen Bertel Lykkegaard Andersen, Ole Weiss Bjerrum, Nana Brochmann Mortensen, Daniel El Fassi, Torben Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Hans Carl Hasselbalch

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

OriginalsprogEngelsk
Publikationsdato15. jun. 2018
StatusUdgivet - 15. jun. 2018
BegivenhedEuropean Hematology Association 23rd congress EHA 2018 - Stockholm , Sverige
Varighed: 14. jun. 201817. jun. 2018

Konference

KonferenceEuropean Hematology Association 23rd congress EHA 2018
LandSverige
ByStockholm
Periode14/06/201817/06/2018

Citationsformater

Mikkelsen, S. U., Kjær, L., Bjørn, M. E., Knudsen, T. A., Sørensen, A. L., Skov, V., Andersen, C. B. L., Weiss Bjerrum, O., Brochmann Mortensen, N., El Fassi, D., Kruse, T., Larsen, T. S., Mourits-Andersen, H. T., Nielsen, C. H., Pallisgaard, N., Thomassen, M., & Hasselbalch, H. C. (2018). SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ΑLPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY. Abstract fra European Hematology Association 23rd congress EHA 2018, Stockholm , Sverige.